Edwards Lifesciences Corp... (EW)
70.60
0.73 (1.04%)
At close: Apr 15, 2025, 3:59 PM
70.05
-0.78%
After-hours: Apr 15, 2025, 06:44 PM EDT
Edwards Lifesciences Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical Heart Valve Therapy Revenue | 240M | 264.3M | 266.1M | 248.2M | 246.6M | 256.3M | 248.2M | 224.1M | 219.7M | 228.5M | 220.8M | 221.3M | 217.4M | 237.4M | 213M | 204.2M | 203.3M | 160.9M | 193.4M | 205.1M | 204.1M | 217.8M | 214.7M | 207.2M | 184.6M | 190.3M | 179.5M | 204.9M | 195.6M | 207.1M | 199.5M | 189.4M | 190.9M | 198.7M | 195.9M | 196.2M | 187.9M | 204M | 196.9M | 206.1M | 203.4M | 214M | 202.6M | 207M | 191.8M | 204.3M | 198.1M | 197.7M | 185.7M | 200.5M | 203.6M | 256.6M | 246.1M | 263.1M | 244.9M |
| Surgical Heart Valve Therapy Revenue Growth | -9.19% | -0.68% | +7.21% | +0.65% | -3.78% | +3.26% | +10.75% | +2.00% | -3.85% | +3.49% | -0.23% | +1.79% | -8.42% | +11.46% | +4.31% | +0.44% | +26.35% | -16.80% | -5.70% | +0.49% | -6.29% | +1.44% | +3.62% | +12.24% | -3.00% | +6.02% | -12.40% | +4.75% | -5.55% | +3.81% | +5.33% | -0.79% | -3.93% | +1.43% | -0.15% | +4.42% | -7.89% | +3.61% | -4.46% | +1.33% | -4.95% | +5.63% | -2.13% | +7.92% | -6.12% | +3.13% | +0.20% | +6.46% | -7.38% | -1.52% | -20.65% | +4.27% | -6.46% | +7.43% | n/a |
| Transcatheter Heart Valves Revenue | 1.02B | 1.04B | 1.01B | 979.4M | 960.9M | 991.6M | 947.9M | 867.7M | 862.3M | 906.9M | 881.3M | 871.5M | 857.8M | 901.5M | 791.7M | 776.2M | 744.6M | 594.3M | 742.2M | 762.5M | 700M | 677.7M | 597.7M | 592.4M | 557.8M | 584.9M | 551.6M | 519.3M | 481.2M | 487.5M | 539.2M | 432M | 410.1M | 418.6M | 367.8M | 334.3M | 296.1M | 281.4M | 268.5M | 267.5M | 267.2M | 219.7M | 189.2M | 183.9M | 172M | 182.1M | 169.7M | 161M | 123.8M | 145.8M | 121.5M | n/a | n/a | n/a | n/a |
| Transcatheter Heart Valves Revenue Growth | -1.47% | +3.05% | +2.91% | +1.93% | -3.10% | +4.61% | +9.24% | +0.63% | -4.92% | +2.90% | +1.12% | +1.60% | -4.85% | +13.87% | +2.00% | +4.24% | +25.29% | -19.93% | -2.66% | +8.93% | +3.29% | +13.38% | +0.89% | +6.20% | -4.63% | +6.04% | +6.22% | +7.92% | -1.29% | -9.59% | +24.81% | +5.34% | -2.03% | +13.81% | +10.02% | +12.90% | +5.22% | +4.80% | +0.37% | +0.11% | +21.62% | +16.12% | +2.88% | +6.92% | -5.55% | +7.31% | +5.40% | +30.05% | -15.09% | +20.00% | n/a | n/a | n/a | n/a | n/a |
| Transcatheter Mitral And Tricuspid Therapies Revenue | 91.1M | 83M | 72.9M | 56M | 52.4M | 47.6M | 41.6M | 31.5M | 29.7M | 27.9M | 27M | 25.3M | 22.3M | 22.1M | 16.3M | 13.1M | 12.1M | 6.1M | 10.5M | 7.2M | 9.7M | 7M | 4.3M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Transcatheter Mitral And Tricuspid Therapies Revenue Growth | +9.76% | +13.85% | +30.18% | +6.87% | +10.08% | +14.42% | +32.06% | +6.06% | +6.45% | +3.33% | +6.72% | +13.45% | +0.90% | +35.58% | +24.43% | +8.26% | +98.36% | -41.90% | +45.83% | -25.77% | +38.57% | +62.79% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 1.33B | 1.17B | 1.19B | 973.6M | 941.2M | 885.1M | 831M | 749M | 717.3M | 741.4M | 616.5M | 559.7M | 574M | 879.4M |
| Europe Revenue Growth | +13.59% | -1.30% | +22.26% | +3.44% | +6.34% | +6.51% | +10.95% | +4.42% | -3.25% | +20.26% | +10.15% | -2.49% | -34.73% | n/a |
| Japan Revenue | 452.4M | 473.6M | 528.9M | 460.1M | 444.7M | 396.8M | 350.3M | 309.3M | 246.2M | 270.8M | 243.6M | 294.1M | 283.7M | 567.6M |
| Japan Revenue Growth | -4.48% | -10.46% | +14.95% | +3.46% | +12.07% | +13.27% | +13.26% | +25.63% | -9.08% | +11.17% | -17.17% | +3.67% | -50.02% | n/a |
| Rest Of World Revenue | 709.2M | 601.4M | 550.2M | 435.8M | 429.4M | 385.6M | 346.4M | 289.7M | 267.3M | 1.05B | 245.8M | 233.7M | 215.3M | n/a |
| Rest Of World Revenue Growth | +17.92% | +9.31% | +26.25% | +1.49% | +11.36% | +11.32% | +19.57% | +8.38% | -74.48% | +326.08% | +5.18% | +8.55% | n/a | n/a |
| United States Revenue | 3.51B | 3.13B | 2.96B | 2.52B | 2.53B | 2.06B | 1.91B | 1.62B | 1.26B | n/a | 939.6M | 812.1M | 605.6M | n/a |
| United States Revenue Growth | +12.01% | +5.72% | +17.73% | -0.63% | +23.23% | +7.74% | +18.07% | +27.94% | n/a | n/a | +15.70% | +34.10% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 421.4M | 450.8M | 489.7M | 478.8M | 439.6M | 468.7M | 436.3M | 411M | 377.3M | 409M | 370.3M | 424M | 364.4M | 374.5M | 330.8M | 338.5M | 307.2M | 274.9M | 307.8M | 347.2M | 306.2M | 308.5M | 280.3M | 288.1M | 269.5M | 274.9M | 256M | 266.7M | 244.6M | 243.8M | 229.6M | 233.6M | 229.6M | 228.8M | 212.7M | 222.3M | 212M | 213.9M | 202.5M |
| Selling, General, and Administrative Revenue Growth | -6.52% | -7.94% | +2.28% | +8.92% | -6.21% | +7.43% | +6.16% | +8.93% | -7.75% | +10.45% | -12.67% | +16.36% | -2.70% | +13.21% | -2.27% | +10.19% | +11.75% | -10.69% | -11.35% | +13.39% | -0.75% | +10.06% | -2.71% | +6.90% | -1.96% | +7.38% | -4.01% | +9.04% | +0.33% | +6.18% | -1.71% | +1.74% | +0.35% | +7.57% | -4.32% | +4.86% | -0.89% | +5.63% | n/a |
| Research and Development Revenue | 253.4M | 272.6M | 285.2M | 270M | 270.3M | 270.3M | 261.2M | 232.2M | 233.6M | 250.8M | 228.6M | 232.8M | 238M | 225.3M | 207M | 195.7M | 195.5M | 182.1M | 187.4M | 193.9M | 195.5M | 191.9M | 171.4M | 163.1M | 161.8M | 154.1M | 143.2M | 146.6M | 142.9M | 134.4M | 128.7M | 114.9M | 113.1M | 112.9M | 102.4M | 98.2M | 101M | 97.5M | 86.4M |
| Research and Development Revenue Growth | -7.04% | -4.42% | +5.63% | -0.11% | 0.00% | +3.48% | +12.49% | -0.60% | -6.86% | +9.71% | -1.80% | -2.18% | +5.64% | +8.84% | +5.77% | +0.10% | +7.36% | -2.83% | -3.35% | -0.82% | +1.88% | +11.96% | +5.09% | +0.80% | +5.00% | +7.61% | -2.32% | +2.59% | +6.32% | +4.43% | +12.01% | +1.59% | +0.18% | +10.25% | +4.28% | -2.77% | +3.59% | +12.85% | n/a |